Breo Ellipta 25 ug/1

Breo Ellipta 25 ug/1 is a combination inhaler containing fluticasone furoate and vilanterol trifenatate. It is designed for respiratory use and is commonly used for managing asthma and chronic obstructive pulmonary disease (COPD). This powder inhaler is manufactured by GlaxoSmithKline LLC.

Breo Ellipta 25 ug/1 is primarily used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). The inhaler combines fluticasone furoate, a corticosteroid, with vilanterol trifenatate, a long-acting beta-agonist. This combination helps to reduce inflammation and relax the muscles in the airways, making it easier to breathe. People often ask, 'What is Breo Ellipta used for?' and the answer is that it is designed to manage symptoms of these chronic respiratory conditions.

Common effects of using Breo Ellipta 25 ug/1 may include improved breathing and reduced symptoms of asthma or COPD. Some users might experience side effects such as headache, throat irritation, or nasal congestion. It is important to note that individual responses can vary, and not everyone will experience the same effects.

Breo Ellipta 25 ug/1 should be used as directed by a healthcare professional. It is important to follow the instructions for proper inhalation technique to ensure effective delivery of the medication. The inhaler should be stored at room temperature and kept away from moisture and heat. Always consult a healthcare provider before starting any new medication.

Breo Ellipta 25 ug/1 may interact with other medications, including beta-blockers, certain antidepressants, and other respiratory drugs. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, alcohol and certain foods may affect the effectiveness of the inhaler.